Novo’s Stratospheric Rise Has Turned Into a $460 Billion Wipeout
Just last month, Novo Nordisk A/S shares seemed to be turning a corner. Analysts were optimistic about the pill version of the Danish drugmaker’s blockbuster Wegovy obesity shot, while investors...
By Lisa Pham · Bloomberg Markets
Just last month, Novo Nordisk A/S shares seemed to be turning a corner. Analysts were optimistic about the pill version of the Danish drugmaker’s blockbuster Wegovy obesity shot, while investors seemed to have priced in any weakness in the former market darling’s sales outlook.